SCHEMBL5045349

SCHEMBL5045349

CC(C)(C)NS(=O)(=O)c1cccc(NC(=O)c2cnn3c(C(F)F)cc(-c4ccc(C(F)(F)F)cc4)nc23)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.60
KDM4E B2RXH2 5/20 0.59
TP53 P04637 3/20 0.59
POLB P06746 3/20 0.59
KMT2A Q03164 4/20 0.59
HTT P42858 1/20 0.59
LMNA P02545 1/20 0.56
ALDH1A1 P00352 3/20 0.56
THRB P10828 1/20 0.54
MAPT P10636 3/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
KIF18A Q8NI77 1/20 0.51
MEN1 O00255 1/20 0.50
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5049985 0.93 MAPK1 (0.57) MAPK1KDM4ETP53POLBKMT2A
SCHEMBL5041991 0.93 MAPK1 (0.57) MAPK1KDM4ETP53POLBKMT2A
SCHEMBL5045180 0.92 KDM4E (0.71) MAPK1KDM4ETP53POLBKMT2A
SCHEMBL5041995 0.91 MAPK1 (0.59) MAPK1KDM4ETP53POLBKMT2A
SCHEMBL5045167 0.91 MAPK1 (0.60) MAPK1KDM4ETP53POLBKMT2A
SCHEMBL5046190 0.91 KIF18A (0.52) MAPK1KDM4ETP53POLBKMT2A
SCHEMBL5045208 0.91 MAPK1 (0.64) MAPK1KDM4ETP53POLBKMT2A
SCHEMBL5041205 0.90 MAPK1 (0.64) MAPK1KDM4ETP53POLBKMT2A
SCHEMBL5045729 0.90 MAPK1 (0.59) MAPK1KDM4ETP53POLBKMT2A
SCHEMBL5048467 0.89 MAPK1 (0.64) MAPK1KDM4ETP53POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7405231-B2 Anticancer agents; inhibitors of the HER-signaling pathway with decreased toxicity, better solubility and improved pharmacokinetic profile; e.g. 1-[4-(4-(2-[(E)-2-(4-Methanesulfinyl-phenyl)-vinyl]-oxazol-4-ylmethoxy)-phenyl)-butyl]-1H-[1,2,3]triazole HOFFMANN-LA ROCHE INC. (US) 2008-07-29 US disclosed
US-20050203064-A1 Novel oxidized thioether derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203064-A1 Novel oxidized thioether derivatives SULT1E1, CYP4F3, GPX4 MAPK1 3921/4885KDM4E 3424/4885TP53 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.